Posted by Michael Wonder on 06 Oct 2020
Department publishes yet another revised agenda for November PBAC meeting
6 October 2020 - This time it is an addition of a late agenda item.
The new item is a submission from Sanofi for dupilumab (Dupixent).
The submission requests that the PBAC review a revised proposal following the March 2020 recommendation for dupliumab for the treatment of patients with chronic severe atopic dermatitis who have had an inadequate response to topical therapies.
The new version (we make it version 4), also notes the correct spelling for Spinraza (nusinersen).
Once again, no notification of this on the PBS website and no notification within the agenda on what exactly has changed.
